Homelessness and Treatment Outcomes Among Black Adults With Opioid Use Disorder: A Secondary Analysis of X:BOT
Authors:
- Marissa Bs JustenMJMarissa Bs Justen
- Jennifer ScodesJSJennifer Scodes
- Martina PavlicovaMPMartina Pavlicova
- Tse-Hwei Ma ChooTCTse-Hwei Ma Choo
- Manesh GopaldasMGManesh Gopaldas
- Angela HaenyAHAngela Haeny
- Onumara OparaOOOnumara Opara
- Taeho Greg RheeTRTaeho Greg Rhee
- John RotrosenJRJohn Rotrosen
- Edward V. Jr NunesENEdward V. Jr Nunes
- Kathryn HawkKHKathryn Hawk
- E. Jennifer EdelmanEEE. Jennifer Edelman
- 5 January 2023
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Addiction Medicine
- Vol. 17 (4) , 463-467
Abstract
Objective: We sought to identify the sociodemographic and clinical characteristics associated with homelessnesss, and explore the relationship between homelessnesss and treatment outcomes among Black individuals. Methods: This is a secondary analysis of the subgroup of Black participants (n = 73) enrolled in “X:BOT,” a 24-week multisite randomized clinical trial comparing the effectiveness of extended-release naltrexone versus sublingual buprenorphine-naloxone (n = 570). Outcomes included medication initiation, return to extramedical use of opioids assessed by both self-report and urine toxicology, and engagement in medications for opioid use disorder (MOUD) treatment at 28 weeks postrandomization. Descriptive statistics were performed. Results: Black participants were mostly unmarried and male, and about a third were aged 21–30 years. Among people experiencing homelessnesss, more were uninsured (45.5% [10/22] vs 19.6% [10/51]), unemployed (77.3% [17/22] vs 64.7% [33/51]), and reported alcohol (40.9% [9/22] vs 23.5% [12/51]) and sedative use (54.5% [12/22] vs 17.6% [9/51]) within the previous 30 days. Compared with housed Black individuals, a slightly higher proportion of Black individuals experiencing homelessnesss successfully initiated study medication (81.1% [18/22] vs 72.6% [37/51]); similar proportions returned to opioid use during the trial (68.2% [15/22] vs 68.6% [35/51]) and were engaged in MOUD at 28 weeks after trial entry (72.2% [13/18] vs 69.7% [23/33]) among participants located for follow-up. Conclusions: These descriptive results among Black patients participating in a trial of MOUD suggest that efficacious MOUD is possible despite homelessnesss with additional clinical supports such as those provided by a clinical trial.Keywords
This publication has 11 references indexed in Scilit:
- Black clients in expansion states who used opioids were more likely to access medication for opioid use disorder after ACA implementationJournal of Substance Abuse Treatment, 2022
- National trends in substance use treatment admissions for opioid use disorder among adults experiencing homelessnessJournal of Substance Abuse Treatment, 2022
- Opioid use disorder treatment for people experiencing homelessness: A scoping reviewDrug and Alcohol Dependence, 2021
- A systematic scoping review of research on Black participants in the National Drug Abuse Treatment Clinical Trials Network.Psychology of Addictive Behaviors, 2020
- Differential adoption of opioid agonist treatments in detoxification and outpatient settingsJournal of Substance Abuse Treatment, 2019
- Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trialThe Lancet, 2018
- White opioids: Pharmaceutical race and the war on drugs that wasn’tBioSocieties, 2017
- Mortality Among Homeless Adults in BostonJAMA Internal Medicine, 2013
- Conducting Research with Racial/Ethnic Minorities: Methodological Lessons from the NIDA Clinical Trials NetworkThe American Journal of Drug and Alcohol Abuse, 2011
- Treating Homeless Opioid Dependent Patients with Buprenorphine in an Office-Based SettingJournal of General Internal Medicine, 2007